FORM PTO-1390 (REV. 11-2000) modified

U.S. DEPART

T 7.46

COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LE CR TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

(NEY'S DOCKET NUMBER 68 US0P

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

CONCERNING A FILI			10/088771							
INTERNATIONAL APPLICATION NO. PCT/JP00/06375	INTERNATIONAL FILING September 19, 2000	DATE	PRIORITY DATE CLAIMED September 20, 1999							
TITLE OF INVENTION Melanin Concentrating Hormone Antago	nist									
			JURA, Shiro TAKEKAWA, Yuji ISHIHARA							
	-		the following items and other information:							
1. This is a FIRST submission of iter										
2. This is a SECOND or SUBSEQU.3. This is an express request to begin		-	71(f)). The submission must include							
items (5), (6), (9) and (21) indicate	ed below.									
	The US has been elected by the expiration of 19 months from the priority date (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2))									
b. 🕱 has been communicated	by the International Bureau.									
c. is not required, as the ap	plication was filed in the United	States Receiving	ng Office (RO/US).							
6. An English language translation of	the International Application as	filed (35 U.S.	C. 371(c)(2)).							
a. is attached hereto.b. has been previously subr	mitted under 35 U.S.C. 154(d)(4)	1								
7. Amendments to the claims of the In	````		35 U.S.C. 371(c)(3))							
a. x are attached hereto (requ	ired only if not communicated by	y the Internation	onal Bureau).							
b. have been communicated	b. have been communicated by the International Bureau.									
c. have not been made; how	vever, the time limit for making s	such amendme	ents has NOT expired.							
d. have not been made and	will not be made.									
8. An English language translation of	the amendments to the claims ur	nder PCT Artic	cle 19 (35 U.S.C. 371 (c)(3)).							
9. 🗶 An oath or declaration of the inven	tor(s) (35 U.S.C. 371(c)(4)).									
10. An English lanugage translation of Article 36 (35 U.S.C. 371(c)(5)).	the annexes of the International	Preliminary E	xamination Report under PCT							
Items 11 to 20 below concern docume	ent(s) or information included:									
11. 🗷 An Information Disclosure State	ment under 37 CFR 1.97 and 1.9	8.								
12. 🗶 An assignment document for rec	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
13. X A FIRST preliminary amendmen	A FIRST preliminary amendment.									
14. A SECOND or SUBSEQUENT	A SECOND or SUBSEQUENT preliminary amendment.									
15. A substitute specification.	A substitute specification.									
16. A change of power of attorney as	A change of power of attorney and/or address letter.									
17. X A computer-readable form of the	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.									
18. A second copy of the published i	A second copy of the published international application under 35 U.S.C. 154(d)(4).									
19. A second copy of the English lar	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).									
Other items or information:										
	Itemized Return Postcard; Certificate of Express Mailing; Express Mail Label No. EL 916492917 US PCT Forms 101, 301, 304, 308, 332; Written Opinion; Date of Deposit March / 9, 2002									
	,									

Recordation Cover Sheet; Cited References (15)

10 JG18 Rec'd PCT/PTQ 19 MAR 2002

U.S. APPLICATION NO. OF kn	18'87'	PCT/JP00/06375		R	ATTORNEY'S DOCKET NUMBER 2648 USOP			
21. The following fees are submared:					CALCULATIONS PTO USE ONLY			
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):								
Neither internation nor international se and International S								
and International Search Report not prepared by the EPO or JPO \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$890.00								
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO								
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00								
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)				\$	890.00			
				>	090.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).								
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$				
Total claims	33 - 20 =	13	x \$18.00	\$	234.00			
Independent claims	103 = DENT CLAIM(S) (if app	7	x \$84.00	\$	588.00			
MULTIFLE DEFLIN			+ \$280.00	\$				
TOTAL OF ABOVE CALCULATIONS = Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.								
-		SI	UBTOTAL =	\$	1,712.00			
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).								
TOTAL NATIONAL FEE =			\$	1,712.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$				
TOTAL FEES ENCLOSED =				\$	1,712.00			
·					ount to be refunded:	\$		
					charged:	\$		
a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 500799 in the amount of \$ 1.712.00 to cover the above fees. A duplicate copy of this sheet is enclosed.								
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPONDENCE TO:			(M.	211	0			
Mark Cr	Mark Chao, PhD, JD							
Takeda Pharmaceuticals North America, Inc. Mark		Chao, PhD, JD						
Suite 500, 475 Half Day Road								
Lincolnshire, IL 60069 USA			37,29	3				
(847)383-3372 fax (847)383-3481			RATION NUMBER					
For C			ustomer No. 23,115					